Y-mAbs Appoints Seasoned Biopharma Executive Peter Pfreundschuh as Chief Financial Officer

Company Overview - Y-mAbs Therapeutics, Inc. is a commercial-stage biopharmaceutical company focused on developing and commercializing novel radioimmunotherapy and antibody-based therapeutic products for cancer treatment [7][9] - The company's product pipeline includes DANYELZA® (naxitamab-gqgk), the first FDA-approved treatment for relapsed or refractory high-risk neuroblastoma [9] Leadership Appointment - Peter Pfreundschuh has been appointed as Chief Financial Officer, effective June 28, 2024, and will report to Mike Rossi, President and CEO [7][11] - Pfreundschuh has extensive experience in the healthcare sector, having previously served as CFO at Voyager Therapeutics and held executive roles at several other biopharmaceutical companies [8][11] Strategic Positioning - The company is at a critical inflection point, gaining U.S. commercial traction with DANYELZA® while advancing its Self-Assembly DisAssembly Pretargeted Radioimmunotherapy (SADA-PRIT) technology platform [11] - The leadership believes that with the new CFO, the company is well-positioned to make strategic decisions that will enhance its mission of improving patient lives [11]